Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

Castle Biosciences Shares Storm Higher After Quadrupling Q3 YoY Revenue

Shares of melanoma and other skin cancers diagnostic firm Castle Biosciences Inc. traded more than 15% higher today after the firm announced Q3/19 financial and operational results. Skin cancer diagnostics company Castle Biosciences Inc. (CSTL:NASDAQ) , which provide...
Streetwise Reports | November 13, 2019 |

Neovasc Shares Climb 80% Upon FDA Premarket Approval Filing for Refractory Angina Device

Shares of specialty cardiovascular medical device company Neovasc Inc. opened more than 100% higher after the firm reported that it submitted a Premarket Approval application to the FDA for its Neovasc Reducer device for use in the treatment of refractory angina. This...
Streetwise Reports | January 3, 2020 |

Biopharma's Phase 3 Trial Results in Migraine 'Robust,' 'Impressive'

These topline data and next steps for the therapeutic are reviewed in a Ladenburg Thalmann report. In a Dec. 30 research note, analyst Matthew Kaplan reported that Ladenburg Thalmann increased its price target on Buy-rated Axsome Therapeutics Inc. (AXSM:NASDAQ) to $...
Streetwise Reports | January 6, 2020 |

Will Trump’s Stimulus Hint Turn Stocks Around?

After Thursday’s rise, stocks went ever deeper into red since. Driven by incoming bad coronavirus news both in the US and abroad, not even Friday’s strong employment data stopped the selling. Monday’s bloodbath even caused tradin...
Monica Kingsley | March 10, 2020 |

Buzz on the Bullboards: Taco Tuesday

The TSX has struggled to find its footing this week, weighed down by escalating hostilities between Israel and Iran. The geopolitical unrest has injected fresh volatility into global markets, with investors seeking safe havens amid fears of broader regional destabilizatio...
Jonathon Brown | 1 day ago |

Buzz on the Bullboards: Cannabis Tops Health Care

(Image via HEXO Corp.) How high can we get? This past week, it has been the question on the minds of traders, when a market roller coaster saw indexes hit record highs while company earnings saw major names soar and fall in equal measure. Tapping into the larges...
Stockhouse Editorial | June 16, 2021 |

Buzz on the Bullboards: Cancer Detection of the Future … Today

(Image via StageZero Life Sciences Ltd.) Even though there is a wide buffet of rich investing opportunities out there that are of high appeal to serious investors and small-cap opportunists in the current market, COVID-19 movements still take the cake. Over the ...
Stockhouse Editorial | April 14, 2021 |

When the levee breaks

In George Steinbeck’s epic novel ‘The Grapes of Wrath’, a poor family of tenant farmers and thousands of other “Oakies” hitch up their wagons to make the trek to California in search of work and a better life. A savage dr...
Richard (Rick) Mills | October 4, 2019 |

US between Scylla and Charybdis

I’m just going to come right out and say it: The United States is not equipped to deal with a pandemic. The nation of 327 million, despite having the number one economy in the world, and by far the most powerful military, is shockingly ill-prepared, not only ...
Richard (Rick) Mills | March 31, 2020 |

Living in a virus-controlled world

As the coronavirus pandemic continues to infect populations, though in some countries it is slowing, talk has shifted to re-opening economies, and to manufacturing a vaccine that drug companies hope will not only work, but can be distributed at large enough doses to provide ...
Richard (Rick) Mills | April 24, 2020 |